Alnylam Pharmaceuticals, Inc.
ALNY
Revenue
500.92M
▼-158.91M▼-24.08%
3 Months ChangeAssets
4.21B
▲195.41M▲4.87%
3 Months ChangeLiabilities
4.17B
▲159.98M▲3.99%
3 Months ChangeFree Cash Flow
-94.49M
▲85.88M▲47.61%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-10-31
Form 10-Q
ID: 0001178670-24-000053
2024-10-31
Form 8-K
ID: 0001178670-24-000052
2024-08-01
Form 10-Q
ID: 0001178670-24-000041
2024-08-01
Form 8-K
ID: 0001178670-24-000039
2024-05-20
Form 8-K
ID: 0001178670-24-000027
2024-05-02
Form 10-Q
ID: 0001178670-24-000023
2024-05-02
Form 8-K
ID: 0001178670-24-000021
2024-03-04
Form 8-K
ID: 0001193125-24-057906
2024-02-15
Form 8-K
ID: 0001157523-24-000253
2024-01-19
Form 8-K
ID: 0001193125-24-011278